George R. Blumenschein

机构：The University of Texas MD Anderson Cancer Center · ORCID：0000-0002-9606-8194

发表论文 725 篇 · 总被引 42960 次 · h-index 81

代表论文

• First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors (2026 · Journal for ImmunoTherapy of Cancer · 被引 1)
• 569 A phase 1/2 study of KSQ-004EX: autologous tumor infiltrating lymphocytes, engineered to inactivate genes encoding SOCS1 and regnase-1, in patients with select advanced solid tumors (2025 · Regular and Young Investigator Award Abstracts · 被引 1)
• Phase 1/2 study of IMC-C103C, a T cell receptor bispecific (MAGE-A4×CD3) ImmTAC targeting MAGE-A4-expressing malignancies (2026 · Journal for ImmunoTherapy of Cancer)
• Long-Term Outcomes After Proton Therapy Versus Intensity Modulated Photon Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Post Hoc Analysis of a Prospective Randomized Trial (2026 · International Journal of Radiation Oncology*Biology*Physics)
• Abstract 1138: Clinical grade circulating tumor DNA methylation predicts outcome to brigatinib plus local consolidative therapy in patients with ALK rearranged NSCLC - Liquid biopsy correlates from the BRIGHTSTAR trial (2026 · Cancer Research)
• Abstract 49: The PER3-RORB axis defines a tumor-suppressive circadian state associated with improved survival in head and neck squamous cell carcinoma. (2026 · Cancer Research)